Efficacy of first (gefitinib and erlotinib) and second-generation (afatinib) TKIs has been widely validated elsewhere [7–10]; it has been demonstrated that when used as first-line therapy in patients with advanced EGFR-mutated NSCLC the overall response rate (ORR) is ~ 70–80%, and the median progression-free survival (PFS) is 10–12 months [10, 11]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.